Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMXYHC7)

• Drug Name: RU-101 Drug Info
• Synonyms: RU-10; Recombinant human serum albumin (ocular, dry eye), R-Tech Ueno

Indication

Disease Entry	ICD 11	Status	REF
Xerophthalmia	5B55.Y	Phase 1/2	[1]

• Cross-matching ID: TTD Drug ID: DMXYHC7

Molecule-Related Drug Atlas

Drug(s) Targeting Serum albumin (ALB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Gadobenate Dimeglumine	DM4VAOG	Schizophrenia	6A20	Approved	[3]
Sodium lauryl sulfate	DMLJ634	Constipation	DD91.1	Approved	[4]
Oxyphenbutazone	DMPZS7U	Arthritis	FA20	Approved	[5]
Iodipamide	DMXIQYS	Gallbladder disease	DC11.3	Approved	[6]
SPI-1005	DM6XFHS	Reperfusion injury	ND56.Z	Approved	[7]
Gadofosveset	DM5V9U1	Imaging	QA0B	Approved	[8]
Albumin Human	DM5JTPU	Hypoalbuminemia	5C53.2	Approved	[9]
Bismuth	DMTKU46	Diarrhea	ME05.1	Approved	[10]
EVANS BLUE	DM5GT1M	Abdominal aortic aneurysm	BD50.4	Approved	[11]
Activated recombinant FVII-albumin fusion protein	DMKY9GI	Hemophilia	3B10.0	Phase 2/3	[12]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Serum albumin (ALB)	TTFNGC9	ALBU_HUMAN	Modulator	[2]

References

• [1] ClinicalTrials.gov (NCT01843894) A Phase 1/2, RU-101 Ophthalmic Solution in Patients With Severe Dry Eye. U.S. National Institutes of Health.
• [2] Albumin as a tear supplement in the treatment of severe dry eye. Br J Ophthalmol. 2003 October; 87(10): 1279-1283.
• [3] Protocol design for high relaxivity contrast agents in MR imaging of the CNS. Eur Radiol. 2006 Nov;16 Suppl 7:M3-7.
• [4] Some properties of the interaction between 2,2'-diselenadibenzoic acid and serum albumins. J Pharm Biomed Anal. 2005 Sep 1;39(1-2):263-7.
• [5] Effect of albumin conformation on binding of phenylbutazone and oxyphenbutazone to human serum albumin. J Pharm Sci. 1982 Feb;71(2):241-4.
• [6] Determining binding sites of drugs on human serum albumin using FIA-QCM. Biosens Bioelectron. 2008 Sep 15;24(1):48-54.
• [7] Transport of ebselen in plasma and its transfer to binding sites in the hepatocyte. Biochem Pharmacol. 1994 Sep 15;48(6):1137-44.
• [8] 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
• [9] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [10] Competitive binding of bismuth to transferrin and albumin in aqueous solution and in blood plasma. J Biol Chem. 2001 Mar 23;276(12):8829-35.
• [11] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [12] ClinicalTrials.gov (NCT01542619) A Safety and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor VIIa With Albumin (rVIIa-FP) in Healthy Male Volunteers. U.S. National Institutes of Health.